ScientiaCME Free CME Courses

  • FREE

    CME: Improving the treatment and management of schizophrenia: an overview of current and novel approaches

    Schizophrenia, by nature, presents manifold challenges to the HCP directing neuropsychiatric care. Not only do practical matters like medication adherence play a role in the success of therapy, but it behooves clinicians to also have a well-informed understanding of the symptomatology and treatment course of the disease. Atypical antipsychotics are the mainstay of initial pharmacotherapy, with oral agents being preferred first. However, they have sometimes been associated with poor patient adherence, which is associated with suboptimal clinical outcomes. In contrast, improving adherence may enhance quality of life and reduce the risk of hospitalization, thereby potentially lowering health resource utilization and its associated costs.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of schizophrenia and the role the neurotransmitters receptors play in it: D2, D3, 5-HT2A
    • Describe the benefits and risks of pharmacotherapy for schizophrenia and take them into account when formulating a treatment plan for different patients
    • Formulate a treatment plan for a variety of patients with schizophrenia, including those exhibiting only negative symptoms
    • Recommend therapy changes in patients who are unable to tolerate a prescribed treatment
    • Identify barriers to care in patients with schizophrenia and develop** strategies to abate them

    Target Audience:

    Healthcare professionals who are: psychiatrists and primary care physicians; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in psychiatry; and those who otherwise commonly care for or clinically encounter patients who have schizophrenia.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/6/2020
    • Expiration of CME credit: 3/6/2022
  • FREE

    CME: Cold agglutinin disease (CAD): Updates from the American Society of Hematology (ASH) 2019 annual meeting

    Cold agglutinin disease (CAD) is a subtype of autoimmune hemolytic anemia (AIHA) and characterized by cold agglutinin (CA) autoantibodies that cause the erythrocytic hemolysis. Also known as primary or idiopathic CAD, it is distinguished further from cold agglutinin syndrome (CAS), which is a complication of known conditions such as malignancy, infection, or autoimmune disease. Little is known about the epidemiology of CAD; one small study estimated incidence of 1 per 1 million people and prevalence of 1 per 16 million people with females twice as likely males to develop the disease and a median age of onset of 67 years.

    By the end of the session the participant will be able to:

    • Describe the pathogenesis and symptomology of AIHA generally and CAD specifically
    • Describe how diagnosis of CAD is distinguished from other subtypes of AIHA and challenges to successful identification of patients
    • Describe present and emerging treatment options for CAD and monitoring parameters for effectiveness of treatment
    • Develop a safe and clinically effective treatment plan including non-pharmacologic and pharmacologic therapy for patients with CAD

    Target Audience:

    The following healthcare professionals (HCPs): hematologists, oncologists, immunologists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CAD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 2/21/2020
    • Expiration of CME credit: 2/21/2021
  • FREE

    CME: Glaucoma: optimizing pharmacotherapeutic management strategies

    Glaucoma, a heterogeneous disease leading to progressive damage to the optic nerve, causes irreversible vision loss and affects up to six million people in the U.S., and just as many worldwide have glaucoma-related bilateral blindness. The prevalence of glaucoma is increasing, and more than 100 million people across the globe will have glaucoma by 2040. Approximately half of all individuals with glaucoma are unaware of their condition due to the asymptomatic nature of the disease. Although the incidence of glaucoma-related blindness has decreased over the last 20 years thanks to effective management strategies, 13% to 40% of people with glaucoma still develop unilateral or bilateral blindness, typically at a rate of 1.1% per year.

    By the end of the session the participant will be able to:

    • Individualize intraocular pressure targets based on known risk factors and patient-specific characteristics, and optimize assessment of intraocular pressure profiles to readily identify peaks and fluctuations
    • Identify first-line pharmacotherapies, laser therapies, and glaucoma implants for lowering intraocular pressure, and select appropriate monotherapies and combination therapies for patients
    • Discuss present and emerging pharmacotherapies currently in clinical development and their mechanisms of action, and apply those therapies to patient cases
    • Describe barriers to care in the treatment of patients with glaucoma and what clinicians may do to aide patients in circumventing them

    Target Audience:

    Healthcare professionals (HCPs) including: comprehensive ophthalmologists and retinal specialists; physician assistants and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with glaucoma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 2/17/2020
    • Expiration of CME credit: 2/17/2022
  • FREE

    CME: Medical and nutritional management of eosinophilic esophagitis in adolescents and adults: therapeutic updates and best practices

    Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by clinical features of esophageal dysfunction and eosinophil inflammation. EoE is mediated by type 2 helper T cell activity and precipitated primarily by dietary antigens. It may affect people of all ages and races, but the prevalence is highest amongst middle-aged Caucasian males. Approximately 30 out of every 100,000 adults in the U.S. are thought to have the condition.

    By the end of the session the participant will be able to:

    • Describe the patholophysiology of EoE in adults and adolescents such that it informs treatment mechanisms
    • Describe the clinical presentation, complications associated with, and diagnosis EoE in adults and adolescents.
    • Identify current drug treatment options and dietary strategies available for the management of EoE, including strengths and weaknesses of each, and apply them to patient cases using evidence-based medicine.
    • Identify issues with current practices for EoE and strategies to address them.

    Target Audience:

    The following healthcare professionals: allergists, immunologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who specialize in the aforementioned fields; and any other healthcare professionals with an interest in or who may clinically encounter patients with EoE.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 2/15/2020
    • Expiration of CME credit: 2/15/2022
  • FEATURED
    FREE

    CME: Coronavirus disease 2019 (COVID-19) preparedness, facts, and management

    In response to the COVID-19 public health emergency, the Centers for Disease Control and Prevention (CDC) has prepared several related informational materials. This activity consists of information that the CDC believes would be immediately useful to healthcare professionals.

    Target Audience: Healthcare professionals who may encounter patients exposed to the 2019 novel coronavirus (2019-nCoV) or patients with confirmed or at risk of developing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.50
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/10/2020
    • Expiration of CME credit: 3/10/2021
  • FREE

    CME: Hemodynamics – Where are We Now?

    Goal-directed therapy (GDT) has been taken as the gospel in critical care since the publication of Rivers et al.’s seminal paper on the topic demonstrating a mortality benefit in patients with severe sepsis and related shock back in late 2001, whose protocols were soon embraced and became ensconced in practice as standards of care, overlapping with other, high-acuity areas of medical specialty like surgery and emergency medicine. However, these initially results later became more mixed and equivocal on the whole when balanced in the context of more recent literature.

    By the end of the session the participant will be able to:

    • Describe the present methods of fluid assessment
    • Describe the present methods of hemodynamic monitoring
    • Given patient cases, reason your approach to fluid management under various clinical circumstances

    Target Audience:

    This program has been designed for a multidisciplinary physician and nurse audience including: ICU / Anesthesia / Peri-op / Intensivists / Trauma / Critical Care

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 12/9/19
    • Expiration of CME credit: 12/9/21
  • FREE

    CME: Applications in Hemodynamics – Taking Us from Here to the Future: Clinical Applications

    Goal-directed therapy (GDT) has been taken as the gospel in critical care since the publication of Rivers et al.’s seminal paper on the topic demonstrating a mortality benefit in patients with severe sepsis and related shock back in late 2001, whose protocols were soon embraced and became ensconced in practice as standards of care, overlapping with other, high-acuity areas of medical specialty like surgery and emergency medicine. However, these initially results later became more mixed and equivocal on the whole when balanced in the context of more recent literature.

    By the end of the session the participant will be able to:

    • Given patient cases, reason your approach to fluid management under various clinical circumstances
    • Given patient cases, balance volume with vasoactive therapy in your hemodynamic stewardship of the patient

    Target Audience:

    This program has been designed for a multidisciplinary physician and nurse audience including: ICU / Anesthesia / Peri-op / Intensivists / Trauma / Critical Care

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 12/9/19
    • Expiration of CME credit: 12/9/21
  • FREE

    CME: Updates in the management of insomnia: therapeutic updates and optimizing treatment

    Insomnia is defined by the dissatisfaction of sleep quality or quantity characterized by having difficulty falling asleep, staying asleep, waking too early, or a combination of these. It is defined as chronic if the condition persists for three months, despite the opportunity for sleep or eradication of external stimulus. Insomnia affects people of all ages, though the likelihood of developing insomnia increases with age: reporting one-third of the adult population having been affected by at least one symptom of insomnia.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of insomnia such that it might inform treatment mechanisms
    • Identify the currently available and emerging pharmacotherapeutic treatments for management of insomnia and apply them to patient cases using evidence-based medicine
    • Evaluate a treatment plan for a specific patient with insomnia to optimize safety and efficacy, suggesting modifications for improvement
    • Describe barriers to care associated with treating patients with insomnia

    Target Audience: The following HCPs: neurologists, psychiatrists, sleep medicine specialists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with insomnia.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/18/2019
    • Expiration of CME credit: 10/18/2021
  • FREE

    CME: Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents: Updates from APA 2019

    ADHD is a common neuropsychiatric disorder, estimated to affect 7.2% of school age children worldwide and 11% in the US. The presence of the disorder is often not detectable until school workload increases, and it has a significant impact on child and adolescent development, health, education, and family situations. There is evidence of a wide variability in clinicians’ ability to diagnose ADHD, suggesting opportunities for improvement and a gap in care that might be remedied by CME.

    By the end of the session the participant will be able to:

    • Summarize the most impactful findings presented at the APA 2019 meeting relating to pediatric ADHD related to disease diagnosis and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to pediatric ADHD related to evaluation of degree therapeutic success and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to pediatric ADHD related to emerging therapies and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to pediatric ADHD related to quantifying benefit and risk of disease progression and apply them to patient cases.

    Target Audience:

    The following healthcare professionals: psychiatrists, primary care physicians, pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in psychiatry; and any other healthcare professionals with an interest in or who clinically encounter pediatric patients with ADHD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/6/19
    • Expiration of CME credit: 10/6/21
  • FREE

    CME: Attention Deficit Hyperactivity Disorder (ADHD) in Adults: Updates from APA 2019

    ADHD is a common neuropsychiatric disorder, affecting more than 2-3% of adults in the United States. ADHD is characterized by inattentive and/or hyperactive symptoms. Inattentive symptoms include inattention, distractibility and procrastination whereas hyperactive symptoms include impatience, restlessness, and impulsiveness. The presence of the disorder has a significant impact on health, education, and family situations.

    By the end of the session the participant will be able to:

    • Summarize the most impactful findings presented at the APA 2019 meeting relating to ADHD in adults related to disease diagnosis and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to ADHD in adults related to evaluation of degree therapeutic success and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to ADHD in adults related to emerging therapies and apply them to patient cases.
    • Summarize the most impactful findings presented at the APA 2019 meeting relating to ADHD in adults related to quantifying benefit and risk of disease progression and apply them to patient cases.

    Target Audience:

    The following healthcare professionals: psychiatrists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in psychiatry; and any other healthcare professionals with an interest in or who clinically encounter pediatric patients with ADHD.

    See full details chevron_right
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/1/2019
    • Expiration of CME credit: 10/1/2021